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Background and Objectives
 
Evidence supporting the use of platelets and plasma in
resuscitation of massive bleedings is questionable. Current consensus guidelines
recommend restrictive use. Our aim was to determine the effect of changing the
transfusion practice on 30-day survival in massively bleeding patients.
 
Materials and Methods
 
Consecutive adult patients receiving more than 10 units of
red blood cells (RBC) within 24 h 2 years prior to (2002–2003) and 2 years after (2005–
2006) a change in transfusion practice were included. In 2004, we implemented
Haemostatic Control Resuscitation (HCR) with preemptive use of platelets and
plasma, administered in transfusion packages, comprising 5 units of RBCs, 5 units of
fresh-frozen plasma and 2 units of platelet concentrates (PC), when massive bleeding
occurred or upon arrival at the emergency room and thereafter directed by thrombe-
lastography throughout the peri- and postoperative period.
 
Results
 
In 2005–2006, the 442 patients received more PCs within 24 h from admission
[mean 5·0 (SD 4·2) vs. 1·7 (2·0); 
 
P 
 
< 0·0001] and had a smaller decrease in platelet
count during the bleeding episode [91·5 (81·2) vs. 119·7 (100·8) 
 
×
 
 10
 
9
 
/l; 
 
P
 
 = 0·0025]
than the 390 patients treated in 2002–2003. Thirty-day mortality was reduced in
2005–2006 (20·4% vs. 31·5%; 
 
P
 
 = 0·0002) and at 90-day (22·4% vs. 34·6%; 
 
P 
 
< 0·0001)
as compared to 2002–2003.
 
Conclusions
 
In patients who experience massive bleeding, HCR with platelets and
plasma, as guided by thrombelastography, is associated with improved survival.
While conﬁrmation from a randomized controlled trial is urgently needed, HCR may
be considered in these patients.
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Introduction
 
Persistent haemorrhage remains a major contributor to
mortality in massively transfused patients [1]. A considerable
proportion of patients with ongoing bleeding develop
coagulopathy. In traumatically injured patients, coagulopathy
is already present on admission of the most seriously injured
patients and is associated with a poor outcome [2,3]. The
complexity of treating massively bleeding patients may
result in a suboptimal transfusion therapy further contributing
to the poor outcome [4,5]. Traditionally, blood banks have
focused on providing compatible blood products of the
highest possible quality to meet the requests from clinicians
relying on the premise that clinician knowledge of existing
transfusion guidelines results in the optimal transfusion
therapy for the bleeding patient [6–8]. Existing guidelines,
however, advocate early administration of crystalloids and
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colloids in conjunction with transfusion of red blood cells
(RBC). According to the guidelines, fresh-frozen plasma (FFP)
and platelets should only be administered when a whole
blood volume or more has been substituted and then only in
patients with excessive or microvascular bleeding and at best
according to conventional laboratory/coagulation analyses.
This approach may cause dilution coagulopathy and
potentially compromise haemostatic ability further in the
most severely bleeding patients [1,9,10]. The recommenda-
tions of existing guidelines are based on the result of
conventional coagulation assays, such as activated partial
thromboplastin time (APTT) and prothrombin time, although
these assays poorly correlate with clinically relevant coagu-
lopathies [11,12]. In contrast, cell-based whole blood viscoe-
lastical assays, such as thrombelastography (TEG), provide
quantitative information of the haemostatic process and
thus give a proﬁle of the haemostatic changes that occur
during clotting [13,14]. This may be a better guide for blood
component therapy in patients presenting with massive
bleeding [9,15–17].
The current transfusion guidelines are now being chal-
lenged. Reports based on retrospective observations indicate
that plasma and platelets should be administered in a 1 : 1 : 1
ratio (i.e. equal parts of RBC, FFP and platelets) to massively
bleeding patients, which simulates the composition of whole
blood [4,18]. Recently, we reported on proactive administra-
tion of FFP and platelets in patients operated for a ruptured
abdominal aortic aneurysm (rAAA), ﬁnding that the post-
operative transfusion requirements and the 30-day mortality
were signiﬁcantly reduced when patients were treated with
platelets and FFP in conjunction with RBCs from the start of
resuscitation [19].
In the present study of massively bleeding patients, we
evaluated the effect of Haemostatic Control Resuscitation
(HCR), entailing preemptive use of platelets and FFP in
tailored transfusion packages immediately massive bleeding
occurred or upon arrival at the trauma centre with subse-
quent transfusion therapy directed by the results of TEG
analysis throughout the peri- and postoperative period.
The hypothesis was that implementing HCR would reduce
mortality in severely bleeding patients receiving more than
10 RBCs within 24 h.
 
Methods
 
We undertook a before and after study using historical
controls. We included all consecutive adult patients (age
 
≥
 
 15 years) who received more than 10 RBCs within 24 h.
Patients treated in 2005–2006 were compared to patients
treated in 2002–2003 in order to determine patient 30-day
and 90-day mortality.
Haemostatic Control Resuscitation for massively bleeding
patients was introduced in collaboration between the
blood bank and the clinicians based on a joint task force
recommendation at our hospital in 2004. The blood bank
introduced the following services: (i) transfusion packages
comprising 5 units of RBCs stored in saline-adenine-glucose
anticoagulated with Macrodex (SAG M) for a maximum of
15 days, 5 units of FFP, and 2 units of platelet concentrates
(PC) each pooled from four donors, stored in T-Sol for a
maximum of 7 days, to be used from the outset in patients
experiencing massive bleeding until the result of the TEG
analysis was available in the emergency or operating room;
(ii) storage of thawed, ready-to-use FFP in the blood bank
for a maximum of 72 h, for use in transfusion packages; (iii)
continuous monitoring of the blood transfusion practice
in patients receiving more than 10 RBCs within 24 h; (iv)
outreach guidance for the treating physicians in order to ensure
preemptive use of platelets and FFP in patients with massive
bleeding; (v) protocol for monitoring of haemostatic com-
petence with TEG and an intervention algorithm for treatment
with plasma and platelets based on the results of the analysis
(Appendix 1); and (vi) educational programme for anaesthe-
siologists concerning functional haemostasis and TEG.
Thrombelastography was implemented as a routine
analysis performed in the blood bank and displayed bedside
in the resuscitation rooms of the trauma centre, operation
theatres, and in the intensive care units (ICU). The taskforce
did not implement any changes in anaesthetic or surgical
procedures or in the intensive care management during
the study period. Speciﬁcally, no changes in the use of
endovascular haemostatic treatment were performed and no
other type of blood products were used.
The following variables were recorded: gender, age,
diagnosis, length of stay (LOS) in the ICU, LOS in hospital,
30- and 90-day follow-up on all cause, overall mortality
recorded from the database of the hospital and the Central
Ofﬁce of Civil Registration. Amounts of transfused RBC, FFP,
and PC the ﬁrst 24 h and at 30 days were obtained from
the database in the blood bank. Conventional laboratory
analyses such as haemoglobin, platelet count, APTT,
international normalized ratio (INR) and serum creatinine
preceding the ﬁrst blood transfusion and at 24 h thereafter
were obtained from the laboratory database. All data were
routinely collected and entered into a study database based
on unique personal identity numbers after approval from
the Danish Data Protection Agency. The regional ethics
committee of Copenhagen approved the waiver of consent,
as all procedures were part of standard care.
 
Statistics
 
Data are presented as mean and standard deviation (SD)
and analysed by the two-sample 
 
t
 
-test or 
 
χ
 
2
 
-test where
appropriate. A multivariate logistic regression analysis
was used to identify independent risk factors for death as 
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outcome. The Hosmer–Lemeshow goodness-of-ﬁt test was
applied to reject the model if 
 
P 
 
< 0·05. Test for collinearity
was performed, and collinearity was suspected with a
variance proportion > 0·5 and condition index > 10 [20]. We
assessed the time to death by Kaplan–Meier analysis using
the log-rank test. All statistical analyses were performed
using SAS 9·1 (SAS Institute Inc., Cary, NC, USA), and a
 
P 
 
< 0·05 was considered statistically signiﬁcant.
 
Results
 
During 2005–2006, 7575 patients received blood transfusions
out of 62 434 adult patients admitted to our hospital
compared to 7370 adult patients receiving blood transfusion
among 58 769 admitted patients in 2002–2003.
In 2005–2006, 442 patients (5·8% of all transfused)
received more than 10 RBCs within 24 h compared to 390
patients (5·3% of all transfused), fulﬁlling the criteria in
2002–2003. There was no signiﬁcant difference between
groups with regard to demographic variables or initial labo-
ratory analyses prior to ﬁrst blood transfusion with regard to
haemoglobin, platelet count, APTT, INR, albumin, bilirubin
or creatinine (Table 1). The most frequent cause of surgery
was abdominal/vascular followed by cardiothoracic and
trauma surgery. Patients treated in 2005–2006 received more
PCs within 24 h and at 30 days (Table 2). The FFP : RBC ratio
in 2005–2006 was 1 : 1·3 compared to 1 : 1·6 in 2002–2003,
 
P 
 
< 0·0001. Patients treated in 2005–2006 presented with a
smaller decrease in platelet count pre to post as compared to
patients treated in 2002–2003 (Table 3). More patients were
admitted to the ICU in 2005–2006 [327 (74·0%) vs. 251
(64·4%), 
 
P
 
 = 0·0026] and patients had a longer ICU stay
[8·3 days (11·9 days) vs. 6·5 (10·5), 
 
P
 
 = 0·03] and a longer
hospital stay (23·5 vs. 19·1, 
 
P
 
  =  0·017) as compared to
patients treated in 2002–2003.
All cause mortality at 30 days was 20·4% (
 
n
 
 = 90) in
2005–2006 compared to 31·5% (
 
n
 
 = 123) in 2002–2003 (
 
P
 
 =
0·0002) and 22·4% (
 
n
 
 = 99) vs. 34·6% (
 
n
 
 = 135) at 90 days
(
 
P 
 
< 0·0001) (Fig. 1). Each RBC transfused during the ﬁrst
24 h was independently associated with a 1·05 increased
odds ratio for death, whereas an increase in platelet count
was independently associated with a 0·994 odds ratio for
decrease in mortality per 1 
 
×
 
 10
 
9
 
/l count increase (Table 4).
A total of 213 patients did not survive 30 days (90 in 2005–
2006 vs. 123 in 2002–2003). Among non-survivors, there
were no signiﬁcant differences between groups with regard
to age, gender, platelet count prior to the ﬁrst transfusion,
type of surgery, admittance to the ICU, LOS in ICU or hospital
LOS, data not shown (available on request). Non-survivors
treated in 2005–2006 received more platelet concentrates at
Table 1 Demographic variables and laboratory results in patients receiving more than 10 units of red blood cells within 24 h in 2005–2006 and 2002–2003
2005–2006 
(n = 442)
2002–2003 
(n = 390) All P-valuea
Age in years 58·3 (18·5) 58·4 (18·4) 58·3 (18·5) 0·97
Male gender 315 (71·3%) 268 (68·7%) 583 (70·1%) 0·42
Type of admission
Abdominal-vascular surgery 231(52·3%) 176 (45·1%) 407 (48·9%) 0·1357
Cardiothoracic surgery 83 (18·8%) 87 (22·3%) 170 (20·4%)
Trauma surgery 60 (13·6%) 61 (15·6%) 121 (14·5%)
Orthopaedic surgery 38 (8·6%) 27 (6·9%) 65 (7·8%)
Miscellaneous 22 (5·0%) 24 (6·2%) 46 (5·5%)
Burn surgery 8 (1·8%) 15 (3·9%) 23 (3·4%)
Pre-bleeding laboratory analyses
Plasma albumin (g/l) 30·7 (8·5) 31·1 (6·8) 31·0 (6·2) 0·77
Plasma bilirubin (μmol/l) 14·6 (15·8) 15·3 (12·4) 14·9 (11·1) 0·91
Creatinine (mmol/l) 0·27 (0·8) 0·25 (0·98) 0·26 (0·87) 0·81
APTT (second) 34·4 (8·0) 33·5 (10·7) 34·0 (9·3) 0·48
International normalized ratio 1·3 (0·5) 1·4 (0·7) 1·4 (0·6) 0·11
Platelet count (109/l) 210·6 (122·0) 208·2 (102·8) 209·1 (113·0) 0·83
Pre-bleeding sample time, from blood 
sampling to ﬁrst transfusion (h)
13·6 (13·1) 11·8 (12·6) 12·7 (12·9) 0·1437
Post-bleeding sample time, from ﬁrst 
transfusion to blood sample (h)
32·6 (12·2) 32·1 (18·8) 33·6 (11·8) 0·4653
Data are mean (standard deviation), if not marked as n %. 
Two-sample t-test and χ2-test.
aDifference between 2005–2006 and 2002–2003. 
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2005–2006 
(n = 442)
2002–2003 
(n = 390) P-value
Number of RBC 24 h 18·0 (12·6) 19·2 (15·8) 0·2409
Number of FFP 24 h 13·5 (12·3) 12·1 (15·2) 0·1489
Number of PC 24 h 5·0 (4·2) 1·7 (2·0) < 0·0001
Number of blood components 24 h 36·5 (27·9) 33·0 (30·4) 0·0816
Number of RBC 30 days 26·6 (24·2) 28·7 (25·5) 0·2263
Number of FFP 30 days 17·5 (17·8) 17·5 (23·5) 0·9489
Number of PC 30 days 7·0 (9·2) 3·4 (7·5) < 0·0001
Number of blood components 30 days 51·1 (48·0) 49·5 (51·0) 0·6444
RBC, red blood cells; FFP, fresh-frozen plasma; PC, platelet concentrate (four donors).
Data are mean (standard deviation). 
Two-sample t-test.
Table 2 Blood component use during and after 
initial bleeding episode in 832 patients receiving 
more than 10 units of red blood cells within 24 h
2005–2006 
(n = 442)
2002–2003 
(n = 390) P-value
Pre-haemoglobin (mmol/l) 7·2 (1·5) 6·9 (1·6)
Post-haemoglobin (mmol/l) 6·7 (0·95) 6·5 (1·0)
Difference pre to post in haemoglobin (mmol/l) 0·55 (1·7) 0·47 (1·9) 0·67
Pre-creatinine (mmol/l) 0·27 (0·8) 0·25 (0·98)
Post-creatinine (mmol/l) 0·69 (1·2) 0·88 (1·6)
Difference pre to post in creatinine (mmol/l) –0·49 (1·4) –0·56 (1·6) 0·62
Pre-international normalized ratio 1·3 (0·5) 1·4 (0·7)
Post-international normalized ratio 1·5 (0·3) 1·5 (0·4)
Difference in international normalized ratio –0·10 (0·5) –0·07 (0·64) 0·70
Pre-APTT (seconds) 33·5 (10·7) 34·4 (8·0)
Post-APTT (seconds) 37·2 (13·1) 37·9 (13·7)
Difference pre to post in APTT (seconds) –3·0 (13·7) –3·0 (13·0) 0·97
Pre-platelet count (109/l) 208·2 (102·8) 210·6 (122·0)
Post-platelet count (109/l) 113·5 (55·8) 92·7 (54·5)
Difference pre to post in platelet count (109/l) 91·5 (81·2) 119·7 (100·8) 0·0025
Data are mean (standard deviation). 
Two-sample t-test.
Table 3 Conventional laboratory measurements 
prior to start of ﬁrst transfusion and 24 h after, in 
832 patients receiving more than 10 units of RBC 
within 24 h
Fig. 1 Kaplan–Meier curve for 90-day survival. 
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24 h [6·4 (5·8) vs. 1·8 (2·1); 
 
P 
 
< 0·0001] and at 30 days [8·9
(11·6) vs. 3·7 (8·2); 
 
P
 
 = 0·0002] and presented with a higher
platelet count 24 h after the bleeding episode [102·3 (52·6) vs.
80·9 (52·1) 
 
×
 
 10
 
9
 
/l] and a smaller decrease in platelet counts
pre to post [62·4 (77·5) vs. 107·5 (91·4) 
 
×
 
 10
 
9
 
/l; 
 
P
 
 = 0·0248] as
compared to patients treated in 2002–2003. Non-survivors
treated in 2005–2006 also received more FFP the ﬁrst 24 h
[18·5 (19·3) vs. 13·3 (14·5), 
 
P
 
 = 0·03] than patients treated in
2002–2003.
 
Discussion
 
The implementation of HCR with preemptive platelets
and plasma in transfusion packages immediately when
massive bleeding occurred or upon arrival at the hospital
and thereafter based on TEG results throughout the peri- and
postoperative period appears to be associated with reduced
mortality in massively bleeding patients. Patients treated
in 2005–2006 received more platelet transfusions, which
resulted in an improved haemostatic competence as
measured by the smaller decrease in platelet count during the
bleeding episode. Both the improved platelet count and the
treatment period 2005–2006 were independently associated
with reduced mortality, after adjustment for relevant
variables, such as age, gender, RBC transfusion, admittance
to ICU, and cause of surgery.
The results indicate that for massively bleeding patients,
adherence to current transfusion guidelines, which are based
on observations from controlled blood loss in the elective
surgical setting and professional consensus [9,10], may not
be optimal. There are several inherent problems with current
guidelines, the concentration of platelets is diluted to less
than 50% and coagulation factors to about 30% before
administering plasma and platelets to massively bleeding
patients and then only when microvascular bleeding occur.
Moreover, the recommended resuscitation regime applies
to all patients, regardless of individual differences in
coagulation factor activity, platelet concentration, the
dynamics of bleeding, and the extent of tissue damage
related to the surgery or trauma, all of which signiﬁcantly
impact patient outcome [21].
Our blood bank therefore introduced thawed, ready–to-use
FFP, which enables immediate resuscitation of massive
bleeding with platelets and plasma organized in transfusion
packages, securing haemostatic competence, as evaluated by
TEG, provided the different components are administered in
parallel and of equal rate [22].
Another major concern regarding resuscitation of
massively bleeding patients is that conventional coagulation
analyses are used to identify those patients in need for
plasma substitution despite that they only describe isolated
fragments of the haemostatic process [11–13]. Furthermore,
Variable
Death within 30-days (n = 213)
Odds ratio (95% CI) P
Platelet count 24 h after ﬁrst transfusion (increase 1 × 109/l) 0·99 (0·989 to 0·998) 0·008
Period 2002–2003 vs. 2005–2006 1·6 (1·05 to 2·4) 0·0288
RBC transfusion in 24 h (increase 1 unit) 1·05 (1·03 to 1·08) < 0·0001
Age (increase 1 year) 1·05 (1·0 to 1·1) < 0·0001
Cause of surgery 0·0151
Trauma vs. abdominal-vascular surgery 1·4 (0·72 to 2·9)
Orthopaedic vs. abdominal-vascular surgery 0·15 (0·04 to 0·67)
Miscellaneous vs. abdominal-vascular surgery 1·9 (0·78 to 4·6)
Cardiothoracic vs. abdominal-vascular surgery 1·2 (0·72 to 2·0)
Burn vs. abdominal-vascular surgery 5·0 (1·3 to 20·0)
Not admitted to the intensive care unit 0·36 (0·16 to 0·82) 0·0151
Time from ﬁrst transfusion to blood sample (increase 1 h) 0·97 (0·93 to 1·01) 0·0787
Time from blood sample to ﬁrst transfusion (increase 1 h) 1·02 (0·99 to 1·05) 0·16
Male gender 1·1 (0·7 to 1·7) 0·69
Platelet count prior to ﬁrst transfusion (increase 1 × 109/l) 0·99 (0·99 to 1·01) 0·59
CI, conﬁdence interval.
Transfusion of fresh frozen plasma and platelets concentrates within 24 h was removed from the model 
because of suspected collinearity with red blood cell transfusion within 24 h (variance proportion > 0·5 
and condition index > 10). (Further data are available on request).
All odds ratios were mutually adjusted for the other variables. Hosmer and Lemeshow goodness-of-ﬁt 
test, P = 0·7381.
Table 4 Multivariate logistic regression analysis 
of risk factors for 30-day mortality in 832 
patients receiving more than 10 RBCs within 24 h 
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platelet count alone does not reﬂect the platelets haemostatic
functionality [23]. Instead, TEG, a whole blood analysis
measuring the viscoelastical properties of the clot and
reﬂecting the kinetics of thrombin generation, seems more
appropriate. TEG has proven superior to conventional
coagulation assays and platelet count in that it reduces
transfusion requirements in patients undergoing liver and
complex cardiac surgery, and TEGs do better predict the need
for blood transfusion in trauma patients [15,17,24].
In the present study, the patients treated in 2005–2006
were monitored by TEG after the initial administration of
transfusion packages and treated with plasma and platelets
according to the TEG results throughout the peri- and
postoperative period. This approach may have contributed
to the reduced mortality related to clinically important
coagulopathies being identiﬁed and the treatment monitored.
This is further corroborated by Plotkin 
 
et
 
 
 
al
 
. who in patients
with penetrating injury demonstrated that TEG hypocoagu-
lability, as evidenced by a decreased Angle and clot strength,
as opposed to the result of conventional coagulation assays,
correlated with increased blood product use [25] and its use
is now suggested by recent international guidelines [9,10].
Previous reports on the outcome of patients requiring
massive transfusion have documented that development of
coagulopathy is associated with poor outcome [2,3,18], and
Borgman 
 
et
 
 
 
al
 
. [26] demonstrated that early and aggressive
replacement of coagulation factors is associated with
improved survival by decreasing death from haemorrhage for
trauma patients requiring massive transfusion. The mortality
was 65% for an FFP : RBC ratio of 1 : 8, 34% for an FFP :
RBC ratio of 1 : 2·5, and 19% for an FFP : RBC ratio of
1 : 1·4, which is comparable to the results of the present
study where an FFP : RBC ratio of 1 : 1·3 was obtained as well
as a mortality of 20% in 2005–2006.
Furthermore, Gonzalez 
 
et
 
 
 
al
 
. [27] reported that coagulopathy
upon arrival to the hospital was not corrected when the
patients entered the ICU despite adherence to pre-ICU
massive transfusion protocols. The likely explanation is inad-
equate pre-ICU haemostatic monitoring and intervention, and
more aggressive pre-ICU intervention to correct coagulopathy
may be effective in decreasing RBC requirement during ICU
resuscitation leading to an improved outcome because of the
association between the extent of RBC transfusion and
increased mortality.
Important differences exist, however, between these
studies and the present. Firstly, the present study describes
the effect of implementing a new transfusion practice
encompassing transfusion packages and TEG, whereas
only retrospective observations without any forms of inter-
ventions included have been reported previously. Secondly,
the present study encompassed 3–4 times more patients than
the studies reported by Borgmann 
 
et
 
 al. and Gonzales et al.
further strengthening the results. Also, previous results in
massively bleeding patients mainly comes from the trauma
setting, whereas the present study included all, unselected
patients receiving massive transfusion and it could be
speculated whether haemostatic control resuscitation
may further reduce mortality also in the trauma population
[28,29].
Importantly, not only plasma but also platelets were
administered from start of resuscitation in the present study
to secure a normal clot strength, which resulted in a higher
platelet count 24 h after start of resuscitation. The multi-
variate analysis demonstrated that an increase in platelet
count was independently associated with a reduction in
mortality. This is in alignment with retrospective observa-
tions [4,18] and with the results from patients operated for
rAAA, where platelet count upon arrival in the ICU was
independently associated with outcome [19]. Platelets are
pivotal for haemostasis, as the activated coagulation factors
assemble on the activated platelets to generate the thrombin
burst, ultimately leading to the conversion of ﬁbrinogen to
ﬁbrin. Furthermore, the platelets interact with ﬁbrin strands
to form the clot [30].
The strength of the present study lies in the inclusion of all
consecutive patients who experienced massive bleeding. It
was conducted at a single centre ensuring the same standard
of care in the two comparable groups of equal size and
inclusion period. We studied two large groups of massively
bleeding patients presented by all surgical specialties, with
no change in the observed distribution of surgical specialties
from one period to another.
The main limitation of our study relates to the lack of
randomization, which was prohibited by the ethics committee
due to the inability to achieve informed consent from these
patients. Another potential confounder is the possibility that
the patients treated in 2005–2006 were less critically ill
than those treated in 2002–2003 and that the difference in
mortality between groups was merely a result of this and not
a consequence of a change in transfusion therapy. However,
more patients were admitted to the ICU, and the surgical
cause of bleeding, pre-bleeding laboratory analyses and the
demographics of the investigated patients underlined that
there were no signiﬁcant differences between the two groups
of patients. The only difference observed between the two
groups of patients who did not survive was the increased
transfusion of platelets and the improved haemostatic
competency, as measured by a smaller decrease in platelet
counts during the bleeding episode, in patients treated in
2005–2006. Although before and after studies are retrospec-
tive in design, all data in our database are prospectively
collected. The use of routine audit data, rather than protocolized
data collected for research purposes, may affect the results.
However, the sample time was not different in the two groups
and adjustment for the effect of sample time did not affect
our multivariate model.© 2008 The Author(s) 
Journal compilation © 2008 International Society of Blood Transfusion, Vox Sanguinis (2009) 96, 111–118
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In conclusion, the present study investigated the effect
of a change in transfusion practice, Haemostatic Control
Resuscitation, towards use of transfusion packages, early
administration of plasma and platelets, and TEG. The
combined effect of interventions seems to have had a
beneﬁcial effect on survival in this small subpopulation of
massively transfused patients; however, it cannot be ruled
out that other interventions not accounted for in our analyses
may have varied between the two groups. A randomized
controlled trial is urgently needed, but until deﬁnitive proof
is available, the transfusion policy could rely on observational
studies as the one presented here.
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Appendix 1 Thrombelastography (TEG) treatment algorithm for patients 
with ongoing bleeding
TEG Parameter Treatment
R 11–14 min 2 × FFP or 10 ml/kg
R > 14 min 4 × FFP or 20 ml/kg
MA 46–50 mm 1 platelet concentrate
MA < 46 mm 2 platelet concentrates
Angle < 52 2 × FFP or ﬁbrinogen
Ly30 > 8% Antiﬁbrinolytics
R, R-time, minutes; MA, maximum amplitude; Ly30, lysis in percent 30 min 
after MA is reached; FFP, fresh-frozen plasma.
One platelet concentrate pooled from the buffy-coat from four donors.